Testicular seminoma after the complete remission of extragonadal yolk sac tumor : Case Report

Background: Between 2% and 5% of malignant germ-cell tumors in men arise at extragonadal sites. Of extragonadal germ cell tumors, testicular carcinoma in situ (CIS) are present in 31-42% of cases, and CIS are reported to have low sensitivity to chemotherapy in spite of the various morphology and to have a high likelihood of developing into testicular tumors. A testicular biopsy may thus be highly advisable when evaluating an extragonadal germ cell tumor. Case presentation: A 36-year-old man was diagnosed as having an extragonadal non-seminomatous germ cell tumor, that was treated by cisplatin-based chemotherapy, leading to a complete remission. In the meantime, testicular tumors were not detected by means of ultrasonography. About 4 years later, a right testicular tumor was found, and orchiectomy was carried out. Microscopically, the tumor was composed of seminoma. Conclusions: We herein report a case of metachronous occurrence of an extragonadal and gonadal germ cell tumor. In the evaluation of an extragonadal germ cell tumor, a histological examination should be included since ultrasonography is not sufficient to detect CIS or minute lesions of the testis. Background Between 2% and 5% of malignant germ-cell tumors in men arise at extragonadal sites. Cytogenetically most extragonadal germ-cell tumors (EGGCTs) i.e., the seminomas and non-seminomas, are similar to their testicular counterparts. But there are CIS in 31-42% of EGGCT patients’ testes. Ultrastructural studies indicate that CIS originate from rather primitive cells and can develop into different categories of germ cell carcinomas. Furthermore, since CIS are reported to respond poorly to chemotherapies, a metachronous development of testicular cancer will possibly occur, in spite of the various morphologies of testicular cancer . In the present case, the etiology of a metachronous appearance of EGGCT and testicular cancer is discussed. Case presentation A 36-year-old man was admitted to our hospital with the chief complaint of right-sided scrotal enlargement. He had previously received treatment for an extragonadal germ cell tumor. At the age of 32, he presented with lumbago. CT showed a retroperitoneal tumor (Figure 1A), and a transabdominal needle biopsy was carried out. Microscopically, the tumor was composed of a yolk sac tumor (Figure 2-A,B). We performed two courses of systemic chemotherapy using bleomycin, etoposide, and cisplatin, leading to a partial response. As the tumor size was not seemed to decrease after the two courses of the chemotherapy, retroperitoneal lymph node dissection was performed, but failed to show any residual viable cells. An ultrasonic study did not reveal any testicular tumors. About 4 years after the previous treatment, he presented with scrotal enlargement and tumor markers such as AFP and HCG╁ were within normal limit. A right orchiectomy was performed on 23 July. Pathology showed the resected tumor was a seminoma with CIS (Figure 3-A,B). No recurrence has been seen since the surgery (Figure 1B). Conclusions There are reports that approximately 4% of patients with EGGCT develop a metachronous testicular cancer despite the use of cisplatin-based chemotherapy, and the cumulative risk of developing a metachronous testicular cancer 10 years after a diagnosis of EGGCT is 10.3%. However, there is disagreement over whether EGGCT is a primary disease or metastatic from the burned-out primary testicular lesion. Actually, burned-out tumors have been detected in 76% of cases of EGGCT. CIS is also found via biopsy in 31-42% cases. Testicular CIS is thought to have resistance to systemic chemotherapies and to develop later to metachronous testicular cancer. In the present case, the EGGCT was a non-seminomatous germ cell tumor including a yolk sac component, whereas the testicular cancer was a seminoma. We believe CIS was present at the time of the treatment of EGGCT and testicular CIS is so primitive that it could differentiate into any type of germ cells. It is also possible that these metachronously developing germ cell tumors developed independently. A testicular biopsy could clarify the relationship between these tumor cells and the expansion of the disease. In the present case no biopsy was done, but an ultrasonic examination ruled out the possibility of testicular CIS. Giwercman et al. emphasized the necessity of histological examinations of the testis upon an evaluation of EGGCT and also urged a careful follow-up for patients with EGGCT who do not have simultaneous testicular cancer. On the other hand, there is an opinion that any patients with retroperitoneal masses should undergo scrotal ultrasound. Comiter et al. showed definite pathological evidence of a burned-out testicular carcinoma in 5 of 6 patients (83%) with presumed extragonadal germ cell tumors and concluded that scrotal ultrasound studies are useful for the evaluation of the palpably normal testes. Kitahara et al. reviewed the incidence of scrotal echogenic leisions with testicular cancers or burned-out tumors of 22 EGGCT patients and found echogenic changes in 17 patients (77.3%). This means that disease was overlooked by ultrasonic examinations in 22.7% of cases. In our case, it is possibile that metachronous testicular cancer oriented in testicular CIS, grew from a burned-out tumor, or was independent of the EGGCT. We should have performed testicular biopsies at the time of the diagnosis of EGGCT and reflect the strategies of treatments of EGGCT. Now we propose a surveillance protocol of EGGCT as Table1, concerning with following four points. 1. As we mentioned, the overall risk of development a testicular tumor is not so high(4-10.3%). 2. The side effect of CIS therapy (whether irradaition, orchiectomy or chemotherapy) are significant, especially concerning fertility and androgen production. 3. Testicular tumors early detected by adequate surveillance respond well to treatments. 4. Testicular biopsy is not entitled to detect all the CIS. Competing interests None declared. Authors’ contribution IK , MU , HY, KN, TT and ND carried out clinical treatments. TM carried out histopathological studies. Acknowledgements We thank the patient for giving consent for publication of this case report. Reference 1. Dueland S, Stenwig AE, Heilo A, Hoie J, Ous S, Fossa SD. Treatment and outcome of patients with extragonadal germ cell tumours--the Norwegian Radium Hospital's experience 1979-94. Br J Cancer. 1998;77(2):329-35. 2. Chaganti RS, Rodriguez E, Mathew S. Origin of adult male mediastinal germ-cell tumours. Lancet. 1994 May 7;343(8906):1130-2. 3. de Bruin TW, Slater RM, Defferrari R, Geurts van Kessel A, Suijkerbuijk RF, Jansen G, de Jong B, Oosterhuis JW. Isochromosome 12p-positive pineal germ cell tumor. Cancer Res. 1994 Mar 15;54(6):1542-4. 4. Daugaard G琄Rorth M琄von der Maase H et al琚Management of extragonadal germ-cell tumors and the significance of bilateral testicular biopsies琚Ann Oncol 1992瑑3瑍283-289 5. Reinberg Y琄Manivel JC琄Fraley EE琚Carcinoma in situ of the testis琚J Urol 1989瑑142瑍243-247 6. Skakkebaek NE琚Carcionam in situ of the testis瑍frequency and relationship to invasive germ cell tumors in infertile men琚Histopathology 1978瑑2瑍157 7. Harland SJ琄Cook PA琄Fossa SD et al琚Risk factors for carcinoma in situ of the contralateral testis in patients with testicular cancer琚An interim report琚 Eur Urol 1993瑑23瑍115-118 8. Bokemeyer C, Hartmann JT, Fossa SD, Droz JP, Schmol HJ, Horwich A, Gerl A, Beyer J, Pont J, Kanz L, Nichols CR, Einhorn L. Extragonadal germ cell tumors: relation to testicular neoplasia and management options. APMIS. 2003 Jan;111(1):49-59; discussion 59-63. 9. Scholz M, Zehender M, Thalmann GN, Borner M, Thoni H, Studer UE. Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol. 2002 Jan;13(1):121-4. 10. Fossa SD, Aass N, Heilo A, Daugaard G, E Skakkebaek N, Stenwig AE, Nesland JM, Looijenga LH, Oosterhuis JW. Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy.Ann Oncol. 2003 Sep;14(9):1412-8.s 11. Giwercman A, von der M aase H, Skakkebaek NE. Epidemiological and clinical aspects of carcinoma in situ of the testis. Eur Urol. 1993;23(1):104-10; discussion 111-4. Review. 12. Mumperow G琄Lauke H琄Holstein AF et al琚Further practical experiences in the recognition and the management of carcinoma in situ of the testis琚Urol Int 1992瑑48瑍162-166 13. Gleich P琚Testicular carcinoma in situ and nonpalpable seminoma eight years after contralateral teratocarcinoma琚Urology 1990瑑36瑍181-182 14. Kimura F琄Watanabe S琄Shimizu S琄F Nakajima琄M Hayakawa琄H Nakamura琚 Primary seminoma of the prostate and embryonal cell carcinoma of the left testis in one patient瑍a case report琚Jpn J Urol 1995瑑86瑍1497-1500 15. Comiter CV, Benson CJ, Capelouto CC, Kantoff P, Shulman L, Richie JP, Loughlin KR. Nonpalpable intratesticular masses detected sonographically. J Urol. 1995 Oct;154(4):1367-9. 16. Kitahara K, Hori J, Tokumitsu M, Saga Y, Hashimoto H, Kaneko S, Yachiku S. Retroperitoneal germ cell tumor with testicular calcification indicating tiny testicular origin: consideration of the origin of retroperitoneal germ cell tumors: report of two cases Hinyokika Kiyo. 2003 May;49(5):291-5. Review. Japanese. Fig. 1-A : CT shows a retroperitoneal bulky mass.